Mercy Medical Center

Running trials

• Recruiting

  Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  NCT07237516· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Source

• Recruiting

  A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

  NCT06562543· Phase 4· Source

• Enrolling by invitation

  Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

  NCT06560021· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Source

• Active, not recruiting

  A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

  NCT05519475· Phase 2· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Source

• Recruiting

  Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  NCT05334069· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

  NCT05306340· Phase 3· Source

• Recruiting

  Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

  NCT05040360· Phase 2· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Source

• Recruiting

  Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

  NCT04588077· Phase 4· Source

• Active, not recruiting

  NCI COVID-19 in Cancer Patients, NCCAPS Study

  NCT04387656· Source

• Active, not recruiting

  A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

  NCT04194775· Phase 3· Source

• Active, not recruiting

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· Phase 3· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Source

• Active, not recruiting

  Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153· Phase 3· Source

• Active, not recruiting

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· Phase 3· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· Source

• Active, not recruiting

  HOT: HIPEC in Ovarian Cancer as Initial Treatment

  NCT02124421· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease3 recruiting
• Colorectal cancer2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Ulcerative colitis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hepatitis B1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting
• Primary biliary cholangitis1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Source

• Completed

  An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

  NCT04950764· Phase 1· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Source

• Completed

  Prevention of Colorectal Cancer Through Multiomics Blood Testing

  NCT04369053· Source

• Completed

  A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  NCT04102098· Phase 3· Source

• Completed

  Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

  NCT03362177· Phase 3· Source

• Terminated

  An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

  NCT03692897· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Source

• Completed

  Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

  NCT02910557· Source

• Completed

  A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

  NCT02815891· Source